# Pacira BioSciences, Inc. (PCRX) — capital_return/buyback_authorization [completed]
Source: SEC API (secapi.ai) · situation sit_9a7f0ea0a13f9e216c16 · retrieved 2026-08-11T16:13:59.492Z

## Overview
Pacira BioSciences develops and commercializes innovative non-opioid pain therapies, including EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain management and ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) for osteoarthritis knee pain, and is advancing PCRX-201, a gene therapy candidate for knee osteoarthritis.

Pacira BioSciences completed the divestiture of its iovera® cryoanalgesia business to Zimmer Biomet Holdings, Inc. on July 31, 2026. Under the transaction terms, Pacira will receive up to $140 million in total consideration: an upfront payment of $70 million (subject to customary adjustments) and potential future revenue-based milestone payments of up to $70 million through December 31, 2031. Pacira received $73.6 million in cash after purchase price adjustments at closing. The parties will also collaborate on advancing the spasticity program, with Pacira eligible for incremental compensation upon successful completion of the registrational study and regulatory approval.

## Terms
- Counterparty: Zimmer Biomet Holdings, Inc. · Deal value: $140.0M · Consideration: cash

## Key dates
- Expiry 2031-12-31 · Completed 2026-07-31

## Timeline
- 2026-08-04 · 8-K (0001628280-26-052527): 8-K - Pacira BioSciences, Inc. — *Pacira BioSciences develops and commercializes innovative non-opioid pain therapies, including EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain management and ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) for osteoarthritis knee pain, and is advancing PCRX-201, a gene therapy candidate for knee osteoarthritis.* Pacira BioSciences completed the divestiture of its iovera® cryoanalgesia business to Zimmer Biomet Holdings, Inc. on July 31, 2026. Under the transaction terms, Pacira will receive up to $140 million in total consideration: an upfront payment of $70 million (subject to customary adjustments) and potential future revenue-based milestone payments of up to $70 million through December 31, 2031. Pacira received $73.6 million in cash after purchase price adjustments at closing. The parties will also collaborate on advancing the spasticity program, with Pacira eligible for incremental compensation upon successful completion of the registrational study and regulatory approval.
  https://www.sec.gov/Archives/edgar/data/1396814/0001628280-26-052527.txt

## Citations
- 0001628280-26-052527 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000162828026052527